Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial

Suzuki, KenshiKenshiSuzukiMin, Chang-KiChang-KiMinKim, KihyunKihyunKimLee, Je-JungJe-JungLeeShibayama, HirohikoHirohikoShibayamaKo, Po-ShenPo-ShenKoSHANG-YI HUANGLi, Sin-SyueSin-SyueLiDing, BifengBifengDingKhurana, MonicaMonicaKhuranaIida, ShinsukeShinsukeIida2023-06-072023-06-072021-120925-5710https://scholars.lib.ntu.edu.tw/handle/123456789/631865Due to increasing use of frontline lenalidomide, effective and safe lenalidomide-free therapies for relapsed/refractory multiple myeloma (RRMM) are needed in Asia. This subgroup analysis of phase 3 CANDOR study evaluated efficacy and safety of KdD vs Kd in Asian patients with RRMM.enAsian population; CANDOR trial; Carfilzomib; Daratumumab; Relapsed refractory multiple myeloma[SDGs]SDG3Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trialjournal article10.1007/s12185-021-03204-9344106352-s2.0-85113141033WOS:000686520300001